Immunotherapy drugs are doubled to live cancer in the judgment of progress

Hundreds of thousands of people who have advanced head and neck cancer, thanks to an immolotherapy drug, it can live longer without cancer, offers a clinical test.

This has been the first sign of progress for patients with this difficult cancer for 20 years, and tell scientists behind the research.

Laura Marston, 45, from Derbyshire, was given the chance to survive after the diagnosis of developed language cancer after the diagnosis of developed language cancer six years ago after the “Dire”.

Received before and after surgery, researchers help to learn to attack cancer when the body returns back.

Cancers in the head and neck, are difficult to treat and patients have been a little change on the way in which the patients were treated in two decades.

More than half of the diagnosis of advanced head and neck cancers die in five years.

Laura was given a chance to be survived so long after the diagnosis in 2019, will not go to a ulcer in the language.

The next step was the main operation to remove the language, as well as the lymph nodes in his neck and then learned to talk again and get food again.

“I was 39 years old and I was devastated,” said BBC news.

As part of an international study involving experts from the Cancer Research Institute in London, Laura in London was one of 350 patients with pembrolizumabia in Laura and the body.

Prof. Kevin Harrington, who led the court in the UK, will give a good chance of good review of the immune system, and then we continue to strengthen the immune reaction by giving a drug to a year. “

He took a similar number of patients diagnosed with a similar number of patients. In one area, there was an advanced head and neck cancer that did not spread to the rest of the body.

The new approach showed positive results. The patients have increased from cancerless, an average of 2.5 to five years to five years.

In three years, patients with pembrolizumab and took 10% lower risk of cancer, elsewhere in the body.

For six years, Laura works in full working day and says “doing a good place and really good work.”

“It’s a phenomenal for me because I am able to talk to you.

“I did not expect to be in the future,” Laura said.

“My prediction was quite terrible.”

The muscle took off the left arm and put it in the mouth to fill the remaining gap from his tongue. It was a difficult journey.

“It’s amazing immolotherapy back my life again.”

The researchers say their consequences, patients with patients’ medicines before surgery, and the patients gave the body to patients and the arrest of cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return to cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return to cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer and return cancer.

Prof. Harrington says “can change the world” for these patients, says immunotherapy.

“This significantly reduces the chances of spreading cancer spread around the body,” he said.

Every year, the UK is diagnosed with 12,800 new head and neck cancer.

Prof. Harrington was “especially good” for some of the approaching patients, but was “really exciting” to see the treatment that benefits all the patients in the trial. Added that now it should be available in the NHS.

The research results are presented in the American Clinical Oncology Society (ASCO) in the annual meeting.

In 24 countries, 192 hospitals participated in the hospital, the Washington University School of Washington, who was attended by Washington University and funded by the MSD.